in early 2015, using different study designs to increase the likelihood of collecting robust efficacy and safety data. In August 2015, the World Health Organization (WHO)-led vaccine trial in Guinea reported promising efficacy [7] .
The Centers for Disease Control and Prevention (CDC) sponsored the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) and conducted it in collaboration with the College of Medicine and Allied Health Sciences, University of Sierra Leone, and the Ministry of Health and Sanitation. We designed STRIVE to accelerate availability of a potentially efficacious vaccine to a high-risk population-healthcare and frontline response workers-while simultaneously evaluating safety and efficacy [8] . Because safety data were limited, especially in African populations, we included a detailed safety substudy. We launched STRIVE after aggressive Ebola control efforts were implemented and after the epidemic peaked; no STRIVE participants developed Ebola so an efficacy assessment was not possible. This report describes safety results from STRIVE, the largest cohort vaccinated with rVSVΔG-ZEBOV-GP reported to date.
METHODS

Study Design and Participants
The STRIVE study was an individually randomized, unblinded Phase 2/3 trial with phased vaccine introduction, no placebo, and concurrent evaluation of vaccine safety and efficacy. Participants were randomized to immediate (within 7 days of enrollment) or deferred (18-24 weeks after enrollment) vaccination ( Figure 1) ; these groups were to be compared for vaccine safety and efficacy. Once vaccinated, deferred participants were termed "crossover-vaccinated" and continued safety follow-up. We randomized participants separately in each of the 7 enrollment sites and minimized site-level imbalance using the Big Stick Design with a maximum imbalance of 3 [9, 10] . We used a group sequential design for efficacy measurement, specifying up to 67 Ebola events during 3 interim and 1 final data analyses dependent on crossing an early stopping boundary. This design had a cumulative power of 80% to reject the null hypothesis of 0% vaccine efficacy if the true efficacy was ≥50% vaccine efficacy or there was a 2-fold infection risk increase with a 2-sided 5% level test. The study started in April 2015 in 5 districts with high Ebola incidence. Participants were healthcare and frontline Ebola response workers ≥18 years old. Exclusion criteria included history of Ebola, current pregnancy (pregnancy testing was required for all women <50 years old), breastfeeding, and self-reported human immunodeficiency virus infection or clinically important immunodeficiency (Appendix). Before crossover vaccination, we repeated screening procedures, including pregnancy testing.
The protocol was approved by the Sierra Leone Ethics and Scientific Review Committee, CDC Institutional Review Board, Pharmacy Board of Sierra Leone, and US Food and Drug Administration (FDA). Participants provided written informed consent. A scientific steering committee provided study design and implementation guidance. An independent data safety monitoring board reviewed study data approximately weekly for the first 4 months, monthly until deferred vaccination was complete, and then every 2 months. When preliminary data from the WHO trial in Guinea trial reported efficacy of rVSVΔG-ZE-BOV-GP in August 2015 [7] , we amended our study protocol to allow early vaccination of deferred participants who were not-yet-vaccinated if they were at increased risk of an Ebola exposure.
Vaccine
The rVSVΔG-ZEBOV-GP is a replication-competent recombinant vaccine [11] . Details on vaccine formulation, reconstitution, and storage are in the Appendix. Participants received a single 2 × 10 7 plaque-forming unit dose by intramuscular injection, were observed for 60 minutes, and counseled on Ebola prevention measures and the need to seek care for possible Ebola symptoms. Women were advised to avoid pregnancy for 2 months after vaccination [12] .
Safety Monitoring
Main Study
From enrollment through 6 months after vaccination, the study staff contacted participants monthly to monitor for adverse events (AEs), suspected Ebola, and pregnancy; thus, deferred participants were monitored for up to 12 months. Safety monitoring was conducted in accordance with FDA guidance [13] . The primary safety endpoint was serious adverse events (SAEs) within 6 months of vaccination; we report the 1-and 6-month results. Participants received a cell phone to access a toll-free hotline for nursing advice and medical referrals; home visits were conducted if participants were not reached by telephone for the monthly call. Women who became pregnant within 2 months of vaccination or enrollment were monitored for external congenital anomalies in their infants that were detectable at birth or during the neonatal period. Study physicians provided free medical care to participants with AEs of concern at designated clinics/hospitals. With the local principal investigator, the study physicians assessed SAEs for expectedness, severity, and causality according to FDA guidance. They attempted a full autopsy after deaths and, if that was not feasible, they conducted a verbal autopsy (a method of gathering health information about a deceased individual to determine his or her cause of death) using standard WHO methodology [13, 14] (Appendix).
Safety Substudy
We enrolled initial participants from one enrollment site (Western Rural) in the safety substudy, which included telephone assessments scheduled on days 1, 3, 7, 14, and 28 and a daily symptom diary card. Endpoints were solicited injection-site and systemic reactogenicity AEs on vaccination day and during the following 7 days, and solicited and unsolicited AEs through 28 days. Solicited AEs of particular interest included joint pain, joint swelling, rash, skin vesicles, and oral ulceration [6] . The SAEs and severe (Grade 3) AEs were assessed for causality.
Monitoring and Laboratory Testing for Ebola
To reduce the risk of unnecessary referral and exposure to an Ebola facility, STRIVE worked with national authorities to modify the Ebola case definition so participants with stable, vaccine-related AEs (eg, fever) within 48 hours of vaccination could be observed at home. Participants with any symptoms consistent with Ebola and not vaccination, any symptom of concern lasting > 24 hours, or any exposure to an Ebola patient were immediately referred for Ebola testing at national laboratories [15] . The CDC Ebola laboratory in Sierra Leone performed confirmatory testing (Appendix).
Statistical Analyses
The safety analysis included all randomized participants with at least 1 monthly follow-up assessment. We calculated the proportion of participants with SAEs overall and within Medical Dictionary for Regulatory Activities (MedDRA) v19.0 specific organ classes (SOC) and preferred terms. We compared groups by randomization status (immediate vs deferred) and vaccination status (vaccinated vs unvaccinated) using Barnard's exact unconditional test. Data from crossover-vaccinated participants are described separately. Because the "intention to treat" (immediate versus deferred) and the "as-treated" (vaccinated versus unvaccinated) results were similar, we report the "as-treated" analyses. In the safety substudy, we similarly compared rates of solicited AEs within 7 and 28 days and during days 5-28, the latter interval chosen based on the timing of postvaccination arthritis and associated conditions reported in studies published after STRIVE initiation [6, 16] . For the safety analyses, we performed all comparisons at the 5% level; no adjustments were made for multiple comparisons.
RESULTS
Study Population
Between April 9 and August 15, 2015, we enrolled 8651 of 8815 eligibility-screened participants across 7 sites in the 5 districts (Figures 1 and 2 ). Eleven women were ineligible because of a positive pregnancy test. After enrollment, 4319 participants were randomized to immediate and 4332 to deferred vaccination. Vaccination for deferred participants occurred from September 19 to December 12, 2015. Overall, 7998 participants were vaccinated, including 96 deferred participants who were eligible for early vaccination in September 2015 due to risk of of Ebola exposure (median time to vaccination of 130 days; range, 94-151).
The median age of participants was 30.7 years (range, 18.0-79.5 years); 60.6% were male. Demographic characteristics and occupations were balanced across vaccination sites and study groups ( Table 1, Supplementary Table 1 ). On enrollment, most participants were working as frontline response workers or nurses; 34.6% of participants worked in an Ebola facility and 39.8% worked in a hospital. Two thirds of participants reported a perceived high risk of Ebola infection.
Safety Monitoring
Main Study
Overall, among the 8651 participants, 132 (1.5%) reported 143 SAEs during follow-up; 54 (1.3%) vaccinated participants (median follow-up, 180 days), and 32 (0.7%) participants during their unvaccinated follow-up [median, 150 days] and 47 (1.2%) during their crossover vaccination follow-up (median, 180 days). No SAEs were considered vaccine-related (Supplementary Table 2 ). The most common SAEs were MedDRA SOC "infections and infestations"; malaria accounted for approximately half of these. Twenty-four (0.2%) study participants died during the 6-month safety follow-up, and 1 additional death occurred during pregnancy follow-up; deaths were balanced across study groups. Among 3993 vaccinated and 4106 unvaccinated participants who completed the 1-month follow-up, the proportion with reported SAEs within 1 month of vaccination or enrollment was significantly higher for vaccinated (0.5%) than unvaccinated participants (0.2%, P = .010) ( Table 2) . A total of 104 gestations in 103 women (43 vaccinated; 60 unvaccinated) occurred with estimated onset within 2 months after vaccination or enrollment. Birth outcomes were unknown for 3 (7.0%) vaccinated and 14 (23.3%) unvaccinated women.
Among those with known birth outcomes, pregnancy losses occurred in 17 (42.5%) vaccinated (including 1 set of twins) and 20 (43.5%) unvaccinated women; 23 vaccinated and 26 unvaccinated women had 49 live births. No congenital anomalies were diagnosed among the 38 infants whose mothers consented to a 28-day follow-up nor in the neonatal death (1 of 2) where a maternal report was available. a Includes nurse, community health nurse, maternal-child health aide, midwife, nurse aide, nursing student, vaccinator.
b Includes dentist, medical counselor, nutritionist, physiotherapist.
c Includes contact tracers, ambulance crew, burial workers, swabbers (took post mortem skin/mucosal swabs for Ebola testing on all deceased people).
d Participants who responded "very high" or "high" are included in the high category.
e Participants who responded "very low" or "low" are included in the low category.
Safety Substudy
The 436 substudy participants (205 vaccinated, 231 unvaccinated) had similar demographic characteristics to the overall study participants, except for a lower median age (27.6 vs 30.7 years; P < .001) (Supplementary Table 3 ). Among the vaccinated substudy participants, 91.2% reported systemic AEs within 7 days of vaccination compared with 35.5% of unvaccinated participants (P < .001); they were more likely to experience fever, feverishness, fatigue, feeling unwell, muscle pain, joint pain, chills, headache, nausea, abdominal pain, rash, and skin vesicles ( Table 3) . Most of these events occurred within 24-48 hours of vaccination and resolved within 5 days (Supplementary Figure 1) . Five (2.4%) vaccinated participants reported severe systemic reactions, most commonly elevated temperature (≥39.0°C) with or without other symptoms (Table 3) . Similar results were observed during the full safety substudy period (0-28 days postvaccination) (Supplementary Table 4 ). Two SAEs were reported in the substudy, malaria in a vaccinated (Table 4) . One vaccinated participant reported severe joint pain during days 21-23 postvaccination. In addition, vaccinated participants were significantly more likely to report skin vesicles (2.0% versus 0%) and oral ulcers (2.0% versus 0%) during the second week postvaccination. Three vaccinated and 1 unvaccinated participant reported joint swelling (P = .303).
Ebola Evaluations
During the efficacy follow-up period, 27 vaccinated and 17 unvaccinated participants had medical conditions that resulted in evaluations for Ebola; no cases were laboratory confirmed. Malaria was reported in 11 of these participants.
DISCUSSION
Responding to an urgent global need during the West Africa Ebola epidemic, we designed and implemented STRIVE in Sierra Leone. The study aimed to provide data on vaccine efficacy, safety, and immunogenicity, provide access to a candidate vaccine in closely monitored settings, and along with 2 other large vaccine trials initiated in the highly Ebola-affected countries, mitigate risk that a single trial would not provide sufficient data for licensure application [17] [18] [19] [20] . In STRIVE, we vaccinated almost 8000 healthcare and frontline response workers, providing safety data from the largest cohort receiving rVSVΔG-ZEBOV-GP vaccine in any trial to date. The STRIVE immunogenicity specimens will be tested using a validated assay and the results reported separately.
In STRIVE, although 0.5% and 1.3% of immediate vaccinated participants reported SAEs within 1 and 6 months of follow-up, respectively, no SAEs were vaccine-related; nor were there any vaccine-related SAEs among crossover-vaccinated participants. The STRIVE's SAE prevalence 1 month postvaccination was lower than in participants receiving rVSVΔG-ZEBOV-GP in the National Institutes of Health (NIH)-sponsored vaccine Abbreviations: CI, confidence interval; N/A, not applicable.
a Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible.
b P value for difference in proportion of vaccinated and unvaccinated participants by Barnard's exact unconditional test.
c Elevated temperature defined as ≥38.0°C for any adverse event and ≥39.0°C for a severe adverse event.
d Totals reflect the number of participants with ≥1 adverse event.
trial in Liberia, and it was lower 6 months postvaccination than subjects receiving the same VSVΔG-ZEBOV-GP dose in the Merck-sponsored lot consistency study; both of these studies conducted in-person follow-up [21] . This may have facilitated more complete SAE ascertainment than STRIVE's telephone follow-up. Within 1 month of enrollment, we found more SAEs reported in the vaccinated than the contemporaneous unvaccinated group. We saw no clear pattern in the SAE reports, suggesting differential seeking of medical care or reporting bias. This is suggested by the fact that in our safety substudy, where events were more actively solicited, SAEs were similar between groups. Mild to moderate symptoms were common in the immediate vaccination period, but they were shortlived and generally well tolerated. Although STRIVE was not double-blind or placebo-controlled, systemic reactions among vaccinated and unvaccinated participants were similar in range to those described in placebo-controlled trials of rVSVΔG-ZE-BOV-GP [16, [20] [21] [22] [23] . Although the number of women who became pregnant within 2 months after vaccination was small, we provide the first reports on outcomes of such pregnancies with reassuring data that no congenital anomalies were detected in their infants. We consider the high rate of reported pregnancy loss in both vaccinated and unvaccinated women to be due to reporting bias. There are no published statistics on pregnancy loss in Sierra Leone. However, in a large cohort of US women, after excluding elective termination of pregnancy, reported pregnancy loss was approximately 20% [24] . Additional data on the safety of vaccination in pregnancy will help guide the development of Ebola vaccination recommendations. Arthritis was reported in the second week after vaccination among a subset of older participants in the Geneva trial [16, 23] , a finding recently confirmed in the Merck lot consistency study [21] . Therefore, we queried specifically for joint swelling in our safety substudy. Consistent with the other Phase 2/3 trials in West Africa [19, 20] , we did not find an association of arthritis or joint swelling with vaccination, although the STRIVE substudy population was small for detecting rare events. The younger median age of our study participants, environmental or genetic differences, or differing methods for participant medical evaluation and follow-up may explain these differences [19, 20] . Nonetheless, we confirmed that vaccination was associated with some symptoms consistent with viral replication such as joint pain, rash, skin vesicles, and oral ulcers at various time intervals during 5 to 28 days postvaccination, most commonly during the second week postvaccination [16, 21, 23] . Although joint pain onset tracked closely with other systemic symptoms during the first 7 days postvaccination with rapid onset and short duration, vaccinated STRIVE participants reported joint pain more frequently than unvaccinated participants during every week from 0 to 28 days postvaccination. In the WHO trial of this b The total may be greater than the sum of the time periods if a participant had the symptom during >1 time period.
c The mean proportion of days with active symptoms among vaccinated versus unvaccinated participants reporting the symptom during days 5-28 was 2.9% versus 0.3% (P < .001) for joint pain, 0.1% versus 0.0% for joint swelling (P = .260), 2.6% versus 0.4% (P = .002) for rash, 1.0% versus 0.1% (P = .189) for skin vesicles, and 0.3% versus 0.0% (P = .189) for oral ulcers.
d One vaccinated participant reported severe joint pain on days 21-23. This participant also reported an SAE of malaria and AE of vaginal discharge during this time period.
e P value for difference in proportion of vaccinated and unvaccinated participants by Barnard's exact unconditional test.
vaccine in Guinea, joint pain was reported by 17.9% of participants 0-14 days postvaccination, most within the first 3 days; there was no comparison group [19] . In the NIH trial in Liberia, there was no difference in reported joint pain between the group that received rVSVΔG-ZEBOV-GP compared with the placebo group [20] . Fever and other systemic symptoms were common within 24-48 hours postvaccination and resolved quickly. Future use of this Ebola vaccine in outbreak responses will need to differentiate vaccine reactions from suspected Ebola to reduce the risk of unnecessary exposure to Ebola in treatment facilities while ensuring that true Ebola cases are properly identified. Our approach, which used a modified Ebola case definition, may be useful in future responses [15] . In the Guinea trial, where participants were given antipyretics for the prevention and management of postvaccination fever, only 0.1%-1.3% of vaccinated adults reported fever within 14 days [19] . They also reported less headache, myalgia, joint pain, and fatigue than STRIVE participants. Routine use of antipyretics to prevent postvaccination symptoms during an Ebola outbreak should be weighed against the possibility of masking Ebola, thereby delaying referral for diagnosis and treatment.
We faced major challenges conducting a large trial during an Ebola epidemic. A contemporaneously enrolled control group was important considering the epidemic dynamics and seasonality of febrile illnesses, including malaria [25] . It was critical not to hire staff away from the response, so STRIVE staff included many students or not-yet-employed graduates in nursing, pharmacy, and medicine; retired nurses; and parttime physicians. Because of the number of participants, large geographic area of the study, and complicated transportation logistics, we conducted routine follow-up by telephone; physicians evaluated participants with more serious illnesses.
CONCLUSIONS
Through strong commitments from global public-private partnerships, the rVSV∆G-ZEBOV-GP vaccine underwent rigorous testing for efficacy, safety, and immunogenicity during the 2014-2016 West African Ebola epidemic. Final results from the WHO trial in Guinea indicated high shortterm efficacy for the vaccine [19] -long-term efficacy was not assessed. The NIH trial in Liberia reported immune responses elicited by rVSV∆G-ZEBOV-GP at 1 month; these responses were largely maintained through 12 months [20] . Our study contributes important safety information from approximately 8000 participants that complements safety, immunogenicity, and efficacy data from these and other vaccine trials; STRIVE immunogenicity data, when available, will provide additional information [16, [19] [20] [21] [22] . The recent re-emergence of Ebola in the Democratic Republic of Congo highlights the ongoing challenges that Ebola will present and the importance of continued commitment to bring Ebola vaccines to licensure. This includes studies on the durability of the immune response and vaccine safety in children [26, 27] . Vaccination is likely to be a critical public health tool for controlling future Ebola outbreaks. Although recent recommendations and experience with use of this unlicensed vaccine cover outbreak response only under the Expanded Access framework [28] , future policies need to consider whether vaccinating certain high-risk groups, such as healthcare and frontline workers, before an epidemic might also be beneficial [26, [29] [30] [31] [32] .
Notes
